CNP-103 / Cour Pharma - LARVOL DELTA

CNP-103: A First-in-Human Phase 1b/2a Study of an Antigen-Specific, Immune-Tolerizing Therapy for Recent-Onset Type 1 Diabetes (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

First-in-human • P1/2 data • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: COUR Pharmaceutical Development Company, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes (GlobeNewswire) - "COUR Pharmaceuticals...today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CNP-103, a nanoparticle in development to address the underlying autoimmunity of Type 1 diabetes (T1D)....We expect to initiate a Phase 1b/2a first-in-human trial of CNP-103 later this year."

IND • Trial status • Type 1 Diabetes Mellitus